Treatment Options After CAR T Therapy for Large B-Cell Lymphoma

Video

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

This content originally appeared on our sister site, OncLive.

Recent Videos
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Related Content
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine and the clinical director of cancer cell therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma

Saurabh Dahiya, MD, FACP;Noah Stansfield;Ashling Wahner;Caroline Seymour
June 14th 2025
Article

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Dual-Target CD19/CD20 CAR T-Cell Therapy Achieves 63.6% Complete Remission Rate in R/R B-NHL

Dual-Target CD19/CD20 CAR T-Cell Therapy Achieves 63.6% Complete Remission Rate in R/R B-NHL

Noah Stansfield
June 13th 2025
Article

The overall response rate for the 11 treated patients was 72.7% at 3 months posttreatment.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Academic CD19-Directed CAR-T Therapy Shows 86.7% ORR in Follicular Lymphoma

Academic CD19-Directed CAR-T Therapy Shows 86.7% ORR in Follicular Lymphoma

Noah Stansfield
June 12th 2025
Article

The data, from a study of 15 patients, were presented at EHA’s 2025 Congress.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital

Deevyashali Parekh, MBBS, on Evaluating the Prevalence of Second Primary Malignancies After CAR T-Cell Therapy

Deevyashali Parekh, MBBS;Noah Stansfield
June 12th 2025
Article

The internal medicine resident at SUNY Upstate Medical University Hospital discussed the implications of findings from a deidentified database of EMR data.

© 2025 MJH Life Sciences

All rights reserved.